期刊文献+

Advances in traditional Chinese medicine for liver disease therapy in 2021 被引量:1

下载PDF
导出
摘要 Liver diseases and their co-morbidities represent a major public health problem.Owing to its progressive pathogenesis and lack of effective treatment,liver disease has become one of the most important causes of death worldwide.Traditional Chinese medicine(TCM)has potential advantages in the prevention and treatment of liver diseases,including high safety,remarkable curative effects,and low toxicity and side effects.In 2021,TCM extracts and their derivatives,TCM compounds,and ethnic medicines showed good efficacy in the treatment of liver diseases.The main mechanisms and representative drugs of TCM can be summarized by the use of amygdalin,dicoumarol,quercetin,and ancient ephedrine decoction to treat hepatitis by inhibiting viral replication,as well as the use of Gentianae Radix,lupeol,Zornia diphylla(L.)Pers.,and Chinese patent medicine Liuwei Wuling tablet to alleviate acute liver injury by improving oxidative stress and inflammatory responses in the body.In the treatment of alcoholic liver disease and metabolic-associated fatty liver disease,the mechanism of TCM is the inhibition of oxidative stress,improving metabolism,regulating intestinal microflora,and enhancing intestinal barrier function.The representative TCM for alcoholic liver disease includes astragaloside,puerarin,patchouli alcohol,and Mori Fructus polysaccharide,while those for metabolic-associated fatty liver disease include saikosaponin,dehydroabietic acid,hesperetin,berberine,and Panax Notoginseng saponins.Additionally,germacrone,forsythin,geniposide,and protocatechuic acid can inhibit the activation or migration of stellate cells and improve liver fibrosis.Toosendanin,paeoniflorin,chrysin,and the classical prescription Huanglian decoction can significantly inhibit the proliferation of liver cancer cells and promote their apoptosis for the treatment of hepatocellular carcinoma.The activation of the farnesol X receptor pathway can improve bile metabolism in the liver,thus,significantly alleviating cholestatic liver disease.Its representative drugs
出处 《Traditional Medicine Research》 2022年第6期100-117,共18页 TMR传统医学研究
基金 the First Clinical Medical School Project of Yunnan University of Traditional Chinese Medicine(No.2021Y10) the Bio-Pharmaceutical Major Science and Technology Special Project of Science and Technology Department of Yunnan Province(No.2019ZF005) the National Natural Science Foundation of China,Youth Science Foundation Project(No.82104802) the Department of Science and Technology of Yunnan Province,General Project of TCM Joint Special Project(No.202101AZ070001-064) the Jiaxing Science and Technology Bureau,Applied Basic Research(No.2022AY10003) the Cangzhou Science and Technology Bureau project(No.213106042) the Department of Science and Technology of Yunnan Province,General Project of TCM Joint Special Project(No.202001AZ070001-058).
  • 相关文献

参考文献7

二级参考文献50

共引文献84

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部